International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 1 Jan-Feb 2021, pp: 1309-1316 www.ijprajournal.com ISSN: 2249-7781

A Review on Management of Hepatic Encephalopathy

Subhodeep Halder[2], Indrajit Bhattacharya[1]
[1,] *Assistant Professor of Pharmacology, Bharat Technology, West Bengal*
[2] *Student, of Bharat Technology, West Bengal*

Date Of Submission: 01-03-2021 Date Of Acceptance: 16-03-2021

ABSTRACT: Hepatic encephalopathy (HE) is a reversible neuropsychiatric dysfunction due to chronic liver disease mainly in liver cirrhosis. The liver plays an important role for detoxification. During cirrhosis of liver, liver cannot detoxify effectively with leads the formation of neurotoxin. Some feature of HE, accumulation of ammonia, known as hyper-ammonemia,swelling of astrocytes due to increase in intracellular osmolality resulting from metabolism of ammonia in astrocytes to form glutamine. The HE is broadlyclassified as either overt HE or minimal HE; overt HE has which is characterized by neurologic and neuropsychiatric.The normal mental status and normal neurologic examination in conjunction with abnormalities on psychometric testing. There is no particular medicine for HE, but main strategy to management of HE is to lowering of ammonia, probiotics therapy and some antibiotic therapy.
KEYWORDS: Astrocytes, liver cirrhosis,neuropsychiatric, neurotoxin, probiotics.

I. INTRODUCTION

The HE is a metabolic disorder that arises in patients with cirrhosis who have a damaged liver. The damaged liver cannot eradicate toxins as a healthy liver normally would. These toxins travel can damage the brain. These HE will occur in the form of acute or chronic disease. [1]] The factor triggered HE like some GI infections, solution issues, or bound medications.[2] The underlying mechanism is believed to involve the build-up of ammonia within the blood, a substance that's usually removed by the liver.[3] The designation is often supported symptoms once ruling out different potential causes. [4] it should be supported by blood ammonia levels, AN graph, or a CT scan of the brain.[1][4]

Acute internal organ nervous disorder can also be a signal of terminal liver failure. Chronic internal organ nervous disorder could also be permanent or repeated. quite four-hundredth of individuals with cirrhosis of the liver develop internal organ nervous disorder.[5] quite half those with cirrhosis of the liver and vital HE live but a year.[6] In those that area unit able to get a liver transplant, the chance of death is a smaller amount than half-hour over the following 5 years.[6] The condition has been delineate since a minimum of 1860.[6]Hepatic nervous disorder usually happens in individuals with chronic disease, like cirrhosis of the liver or infectious disease. Triggers embrace infection and de-hydration.Early symptoms embrace forgetfulness, confusion and breath with a sweet or musty odour. Advanced symptoms embrace shaking of the hands or arms, disorientation and thick speech.

Treatment includes removing noxious substances from the internal organ. internal organ brain disorder nervous disorder-|neurological disorder-neurological disease} will occur in people with acute or chronic liver (hepatic) disease or in people whose liver is bypassed by a porto-systemic shunt (with no disease present). A porto-systemic shunt is an abnormal passageway that permits blood from the channel to bypass the liver. they'll be gift at birth (congenital) or noninheritable throughout life. internal organ nervous disorder is caused once toxins that area unit usually cleared from the body by the liver accumulate within the blood, eventually traveling to the brain. several of the symptoms of internal organ nervous disorder area unit reversible once promptly detected and treated.

II. CLASSIFICATION OF THE HE:

Type A: Encephalopathy from acute liver failure.
Type B: Encephalopathy caused by porto-systemic shunting, without intrinsic liver disease
Type C: Encephalopathy of cirrhosis associated with porto-systemic shunting: Episodic: precipitated, spontaneous, or recurrent Resistant: mild, severe, treatment-dependent Minimal: previously known as ‘‘subclinical’’.

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 1 Jan-Feb 2021, pp: 1309-1316 www.ijprajournal.com ISSN: 2249-7781

III. PATHOPHYSIOLOGY:

There are lots of factor related to pathophysiology of HE.

Pathophysiological role of ammonia in HE: Ammonia has been implicated as a key molecule in HE. Excess ammonia in the body has long been thought to arise from colonic bacterial species with urease enzyme ctivity, predominantly gram-negative anaerobes, Enterobacteriaceae, Proteus, and Clostridium species.[N1-4] In terms of excretion, the kidneys can remove a significant amount of ammonia in the urine, either as ammonium ion (NH4 +) or in the form of urea. The kidneys can also generate ammonia by metabolizing glutamine via glutaminase to ammonia, bicarbonate, and glutamate. This ammoniagenesis primarily serves a role in acid-base homeostasis, since bicarbonate is also produced during the reaction; ammoniagenesis thus serves to buffer systemic acidosis as well as release hydrogen ions into the urine in the form of NH4 +. Whether renal ammonia is released into the urine or returned to the circulation via the renal vein depends upon several factors, predominantly pH. Under physiologic conditions, approximately 30–50% of renal ammonia is released into the urine, while the remainder is returned to the circulation via the renal vein. However, during periods of acidosis, the kidneys can increase the
amount of NH4 + released into the urine several fold.[N 6]In contrast, alkalosis causes a significant decrease in urinary loss of ammonia and can consequently contribute to hyper-ammonemia.

Cerebral ammonia detoxification happens via amino acid synthetase, solely expressed in cerebral astrocytes, within the formation of amino acid, that is a crucial precursor of the most excitant and repressive neurotransmitters: salt and gamma- hydroxybutyric acid (GABA), severally. glial cell amino acid accumulation exerts associate degree diffusion impact leading to swelling and cytotoxic oedema, that results in inflated brain water on resonance imaging and worsening HE.[26]

Contributing factors toward pathophysiology of HE

The utility of categorizing the severity of HE accurately and with efficiency serves not solely to produce sensible useful info concerning this clinical standing of the patient however offers valuable prognostic information and presents objective standards for analysis and trials involving HE. this challenge so is of initial instructive what's "normal", as Associate in Nursing absence of HE doesn't essentially equal absence of neuropsychometric abnormality [23], so crucial optimum ways by that early HE are often systematically and accurately distinguished. Montagnese et al. [23] advocate the benefits of considering Associate in Nursing individual's womb-to-tomb neuropsychometric performance and co-morbidity in crucial whether or not any abnormality equates to HE.



4 Role of ammonia in hepatic encephalopathy :

Amonnia:

Ammonia has long been thought to be the key metabolic issue underpinning the event of HE since the first description of the "meat intoxication syndrome" in portacaval- shunted dogs at the top of the nineteenth century.[24] within the presence of liver failure, belittled utilization of ammonia as a substrate within the viscus organic compound cycle (the major class ammonia detoxification pathway) and portosystemic shunting cause the buildup of ammonia in the circulation, that without delay crosses the blood–brain barrier.[25] Cerebral ammonia detoxification happens via amino acid synthetase, solely expressed in cerebral astrocytes, within the formation of amino acid, that is a crucial precursor of the most excitant and repressive neurotransmitters: salt and gamma- hydroxybutyric acid (GABA), severally. glial cell amino acid accumulation exerts associate degree diffusion impact leading to swelling and cytotoxic oedema, that results in inflated brain water on resonance imaging and worsening HE.[26]

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 1 Jan-Feb 2021, pp: 1309-1316 www.ijprajournal.com ISSN: 2249-7781

Factors contributing to the pathogenesis of HE and treatment mechanisms and emphasis on the interorgan effects of ammonia and inflammation arising due to liver disease.

IV. DIAGNOSIS AND DIFFRENTIAL TESTING

Diagnosis:

The identification of viscus neurological disorder may be a clinical one, once different causes for confusion or coma are excluded; no check totally diagnoses or excludes it. liquid body substance ammonia levels are elevated in ninetieth of individuals, however not all hyperammonaemia (high ammonia levels within the blood) is related to neurological disorder.[30][31] A CT scan of the brain typically shows no abnormality except in stage IV neurological disorder, once brain swelling (cerebral oedema) could also be visible.[31] different neuroimaging modalities, like resonance imaging (MRI), aren't presently thought to be helpful, though they will show abnormalities.[27] Electroencephalography shows no clear abnormalities in stage zero, though smallest he's present; piecemeal I, II and III there are triphasic waves over the frontal lobes that oscillate at five cycle per second, and in stage IV there's slow brain wave activity.[28] but, the changes in electroencephalogram aren't typical enough to be helpful in identifying viscus neurological disorder from different conditions.[29]

Once the identification of neurological disorder has been created, efforts are created to exclude underlying causes (such as listed higher than in "causes"). this needs blood tests (urea and electrolytes, origin count, liver operate tests), typically a chest X-ray, and uranalysis. If there's pathology, a diagnostic abdominocentesis (removal of a fluid sample with a needle) could also be needed to spot spontaneous microorganism redness (SBP).[32]

Laboratory testing:

Laboratory Testing In patients with known cirrhosis of the liver and suspected internal organ brain disease, laboratory testing serves a crucial role in characteristic causative factors and in excluding different causes of altered thought. Common laboratory testing includes assessment of liver and nephritic perform, electrolytes, glucose, cultures, and drug screening. though blood vessel and blood vessel ammonia levels could correlate with the severity of internal organ brain disease, the blood sample has be to collected while not the utilization of a patch and should be transported on ice to the laboratory to be analyzed among twenty minutes to make sure accuracy of the results.[33] additionally, there are several non-hepatic causes of hyperammonemia, like canal haemorrhage, failure, hypovolaemia, intensive muscle use, carbamide cycle disorder, channel nutrition, urosepsis, and use of bound medications (e.g. valproic acid). though patients with internal organ brain disease have elevated humor ammonia levels, the severity of internal organ brain disease doesn't correlate with humor ammonia levels on the far side an explicit purpose.[34,35] For all of those reasons, getting humor ammonia levels to diagnose internal organ brain disease isn't suggested, however if the take a look at was ordered and therefore the result was traditional, the identification of internal organ brain disease ought to prompt a evaluation.[36] If a patient has known internal organ brain disease and is receiving medication treatment to specifically lower ammonia levels, serial observance of blood ammonia levels could also be wont to assess efficaciousness of treatment.[36]

Electroencephalography:

Electroencephalography (EEG) will assess for delicate internal organ nervous disorder and is a lot of objective than psychological science tests, however it's conjointly nonspecific because it may be plagued by alternative metabolic disturbances. It needs special instruments and therefore isn't ordinarily employed in clinical observe.[5]

Prevention of Recurrent Hepatic Encephalopathy:

Once patients demonstrate clinical improvement, management then transitions to the interference of repeated viscus neurological disease, together with reinforcement of compliance with treatment. medical care for viscus neurological disease is also discontinued if a precipitant is known and fitly managed in patients World Health Organization don't have a previous history of obvious hepatic encephalopathy. massive dominant spontaneous portosystemic shunts is embolized in choose patients with affordable liver perform resulting in improvement or resolution of obvious viscus neurological disease.

V. TREATMENT OPTION

Medical Therapy for Overt Hepatic Encephalopathy:

Rapid response to first-line medical medical aid supports the designation of viscus brain disorder. Most patients can respond inside twenty

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 1 Jan-Feb 2021, pp: 1309-1316 www.ijprajournal.com ISSN: 2249-7781

four to forty eight hours of initiation of treatment. Prolongation of symptoms on the far side seventy two hours despite makes an attempt at treatment ought to prompt any investigation for alternative causes of altered cerebration. In most things, the popular approach is to initiate empiric medical aid for viscus brain disorder and concomitantly assess for different causes of altered mental standing and determine causative causes.

Antimicrobial Therapy:

The goal of antimicrobial medical care is to change the gut microbiota to make a additional favorable microbiome that leads to lower endogenous microorganism production of ammonia. Rifaximin is currently the popular antimicrobial agent for the treatment of overt internal organ nervous disorder.

Rifaximin:

The oral antimicrobial rifaximin is minimally absorbed (less than zero.4%) and has broad-spectrum activity against gram-positive, gram-negative aerobic, and anaerobic microorganism. Rifaximin (550 mg double daily) has been shown to be effective in treating internal organ brain disease.[37] during a massive, multicenter trial, rifaximin with lactulose maintained remission from internal organ brain disease higher than lactulose alone and additionally reduced the quantity of hospitalizations involving hepatic encephalopathy.[38] though rifaximin is typically well tolerated, lactulose ought to be used because the initial first-line treatment with rifaximin used as add-on medical care if required.[38,39]

Neomycin:

The oral antimicrobial antibiotic drug reduces microorganism production of ammonia by inhibiting the catalyst activity of glutaminase, associate degree catalyst that converts aminoalkanoic acid to salt and ammonia.[40,41] Oral antibiotic drug (1 to four g daily in divided doses) has been Page 9/27 shown to own some effectiveness for the treatment of internal organ nervous disorder, however this agent isn't habitually used due to major potential adverse effects, as well as ototoxicity and nephrotoxicity.[40,42,44] antibiotic drug ought to be thought-about solely as another agent for treating unconcealed internal organ nervous disorder.[39]

Metronidazole:

Treatment of open viscus neurological disease with Flagyl targets the treatment of gram-negative anaerobic gut microorganism. These anaerobic microorganism manufacture enzyme that hydrolyzes carbamide to ammonia; decreasing the number of anaerobic organisms is postulated to lead to shrivelled ammonia production within the gut.[40] In one study, oral Flagyl two hundred mg four times daily had similar effectiveness as fradicin.[43] long-run use of Flagyl is related to potential neurotoxicity. Flagyl ought to be thought of solely as another agent for treating open viscus neurological disease.[39]

Diet:

In the past, it absolutely was thought that consumption of supermolecule even at traditional levels increased the danger of internal organ neurological disease. This has been shown to be incorrect. moreover, many of us with chronic disease are malnourished and need adequate supermolecule to take care of a stable weight. A diet with adequate supermolecule and energy is so counseled.[30][45]

Dietary supplementation with branched-chain amino acids has shown improvement of neurological disease and different complications of liver disease.[30][45] Some studies have shown advantage of administration of probiotics ("healthy bacteria").[45]

Lactulose/lactitol:

Lactulose and lactitol ar disaccharides that don't seem to be absorbed from the alimentary canal. they're thought to decrease the generation of ammonia by microorganism, render the ammonia inabsorbable by changing it to ammonium ion (NH_4^+) ions, and increase transit of internal organ content through the gut. Doses of 15-30 cubic centimetre ar generally administered thrice on a daily basis; the result's aimed to be 3–5 soft stools a day, or (in some settings) a stool pH of <6.0.[30][31][45][46] Lactulose may lean by clyster, particularly if neurological disorder is severe.[46] a lot of usually, phosphate enemas ar used. this might relieve constipation, one among the causes of neurological disorder, and increase internal organ transit.[30]

Lactulose and lactitol ar useful for treating viscus neurological disorder, and ar the suggested first-line treatment.[30][47] [needs update] Lactulose doesn't seem to be more practical than lactitol for treating folks with viscus neurological

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 1 Jan-Feb 2021, pp: 1309-1316 www.ijprajournal.com ISSN: 2249-7781

disorder.[47] facet effects of lactulose and lactitol embody the likelihood of diarrhoea, abdominal bloating, gassiness, and nausea.[19] In acute liver failure, it's unclear whether or not lactulose is helpful. The doable facet impact of bloating might interfere with a liver transplant procedure if needed.[48]

Antibiotics:

The antibiotic rifaximin could also be counseled additionally to lactulose for those with continual unwellness.[6] it's a nonabsorbable antibiotic from the rifamycin category. this can be thought to figure in an exceedingly similar thanks to different antibiotics, however while not the complications connected to fradicin or Flagyl. thanks to the long history and lower price of lactulose use, rifaximin is usually solely used as a second-line treatment if lactulose is poorly tolerated or not effective. once rifaximin is further to lactulose, the mixture of the 2 could also be more practical than every part on an individual basis.[30] Rifaximin is dearer than lactulose, however the value could also be offset by fewer hospital admissions for nervous disorder.[46]

The antibiotics fradicin and Flagyl ar different antibiotics wont to treat internal organ nervous disorder.[49] The explanation of their use was the very fact that ammonia and different waste product ar generated and regenerate by enteral bacterium, and killing these bacterium would scale back the generation of those waste product. fradicin was chosen owing to its low enteral absorption, as fradicin and similar aminoglycoside antibiotics could cause deafness and kidney disease if utilized by injection. Later studies showed that fradicin was so absorbed once taken orally, with resultant complications. Flagyl, similarly, is a smaller amount ordinarily used as a result of prolonged use will cause nerve harm, additionally to gi aspect effects.[30]

L-ornithine and L-aspartate:

The combination of L-ornithine and L-aspartate (LOLA) lowers the amount of ammonia in an exceedingly person's blood.[50] terribly weak proof from clinical trials indicates that LOLA treatment might profit folks with internal organ neurological disorder.[50] LOLA lowers ammonia levels by increasing the generation of organic compound through the organic compound cycle, a metabolic pathway that removes ammonia by turning it into the neutral substance organic compound.[citation needed] LOLA could also be combined with lactulose and/or rifaximin if these alone area unit ineffective at dominant symptoms.[30]

VI. CONCLUSION

HE is a serious complication of acute or chronic liver disease. The pathophysiology of HE is yet to be fully elucidated. Current treatments are based on reducing intestinal ammonia load by agents, such as antibiotics or disaccharides. However, their efficacy is yet to be clearly established. The mainstay of therapeutic management remains the correction and treatment of an eventual precipitating factor.The pathophysiology of hepatic encephalopathy is complex and multifactorial, but converging evidence points to important contributions of both bacterial flora and bacterial pathogens. The enteric flora is hypothesized to be the major source of ammonia, the primary toxin implicated in hepatic encephalopathy. Moreover, the enteric flora generates other neurotoxic products, such as phenols and mercaptans, that may potentiate the effects of ammonia. Bacteria may also constitute a primary source of the benzodiazepine-like compounds implicated in neuropsychiatric symptoms in liver disease. New evidence suggests that acute bacterial infections, long recognized as important precipitants of hepatic encephalopathy, may mediate clinical worsening through effects on systemic inflammatory responses. Considered together, these data suggest wide-ranging pathophysiological contributions of bacteria to hepatic encephalopathy and underline the potential for an integral role of antibiotics and other bactericidal agents in its management.

REFERENCES

[1]. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI(January 2010). "Current concepts in the assessment and treatment of hepatic encephalopathy". QJM. 103 (1): 9–16.
[2]. Starr, SP; Raines, D (15 December 2011). "Cirrhosis: diagnosis, management, and prevention". American Family Physician. 84 (12).
[3]. "Hepatic encephalopathy". GARD. 2016. Archived from the original on 5 July 2017. Retrieved 30 July 2017
[4]. "Portosystemic Encephalopathy - Hepatic and Biliary Disorders". Merck Manuals Professional Edition. Retrieved 25 September 2019.

[5]. Ferri, Fred F. (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 577.
[6]. Wijdicks, EF (27 October 2016). "Hepatic Encephalopathy". The New England Journal of Medicine. 375 (17): 1660–1670.
[7]. Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC. The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 2013;141:2671–8.[PubMed][CrossRef][Google Scholar]
[8]. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–63.[PubMed][CrossRef][Google Scholar]
[9]. Merli M, Lucidi C, Pentassuglio I. et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol 2013;59:243. [PubMed] [Google Scholar]
[10]. Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010;55:2381–90.[PubMed][CrossRef][Google Scholar]
[11]. Weissenborn K. Challenges in diagnosing hepatic encephalopathy. Neurochem Res. 2015;40:265–73.[PubMed][CrossRef][Google Scholar]
[12]. Zhang Z, Zhai H, Geng J, et al. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108(10):1601–1611. [PubMed] [Google Scholar]
[13]. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39(5):1441–1449. [PubMed] [Google Scholar]
[14]. Davuluri G, Krokowski D, Guan BJ, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;65(5):929–937. [PMC free article] [PubMed] [Google Scholar]
[15]. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104(6):1382–1389. [PubMed] [Google Scholar]
[16]. Córdoba J, Gottstein J, Blei AT. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis. J Hepatol. 1998;29(4):589–594. [PubMed] [Google Scholar]
[17]. Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol. 2004;41(4):613–620. [PubMed] [Google Scholar]
[18]. Aggarwal S, Kramer D, Yonas H, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: a retrospective study. Hepatology. 1994;19(1):80–87. [PubMed] [Google Scholar]
[19]. Marini JC, Broussard SR. Hyperammonemia increases sensitivity to LPS. Mol Genet Metab. 2006;88(2):131–137. [PubMed] [Google Scholar]
[20]. Bai G, Rama Rao KV, Murthy CR, Panickar KS, Jayakumar AR, Norenberg MD. Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J Neurosci Res. 2001;66(5):981–991. [PubMed] [Google Scholar]
[21]. Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5(Suppl 1):S7–S20. [PMC free article] [PubMed] [Google Scholar]
[22]. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol. 2011;54:1030–40.[PubMed][CrossRef][Google Scholar]
[23]. Montagnese S, De Rui M, Angeli P et al. Neuropsychiatric performance in patients with cirrhosis: who is "normal"? J Hepatol 2017;66:825–835.[Google Scholar]
[24]. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-

1008.e1.CrossrefPubMedWeb of Science® Google Scholar

[25]. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071- 1081.Crossref CASPubMedWeb of Science®Google Scholar

[26]. Bajaj JS, Heuman M, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz R, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.Crossref CASPubMedWeb of Science®Google Scholar

[27]. Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol. 2004;41:613–20.[PubMed][CrossRef][Google Scholar]

[28]. Bosoi CR, Rose CF. Oxidative stress: a systemic factor implicated in the pathogenesis of hepatic encephalopathy. Metab Brain Dis. 2013;28:175–8.[PubMed][CrossRef][Google Scholar]

[29]. Rama Rao KV, Norenberg MD. Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem Int. 2012;60:697–706.[PubMed][CrossRef][Google Scholar]

[30]. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI (January 2010). "Current concepts in the assessment and treatment of hepatic encephalopathy". QJM. 103 (1): 9–16

[31]. Chung RT, Podolsky DK (2005). "Cirrhosis and its complications". In Kasper DL, Braunwald E, Fauci AS, et al. (eds.). Harrison's Principles of Internal Medicine (16th ed.).

[32]. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002). "Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998". Hepatology. 35 (3): 716–21

[33]. Ito T, Ikeda N, Watanabe A. et al. Obliteration of portal systemic shunts as therapy for hepatic encephalopathy in patients with non-cirrhotic portal hypertension. Gastroenterol Jpn 1992;27:759–64. [PubMed] [Google Scholar]

[34]. Panickar KS, Jayakumar AR, Rama Rao KV. et al. Downregulation of the 18-kDa translocator protein: effects on the ammonia-induced mitochondrial permeability transition and cell swelling in cultured astrocytes. Glia 2007;55:1720–7. [PubMed] [Google Scholar]

[35]. Montes S, Alcaraz-Zubeldia M, Muriel P. et al. Striatal manganese accumulation induces changes in dopamine metabolism in the cirrhotic rat. Brain Res 2001;891:123. [PubMed] [Google Scholar]

[36]. Conn HO. Hepatic encephalopathy In: Schiff L, Schiff ER. (eds). Diseases of the Liver, 7th edn. Philadelphia: Lippicott, 1993. [Google Scholar]

[37]. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22:125–38.[PubMed][CrossRef][Google Scholar]

[38]. Coltart I, Tranah TH, Shawcross DL. Inflammation and hepatic encephalopathy. Arch Biochem Biophys. 2013;536:189–96.[PubMed][CrossRef][Google Scholar]

[39]. Amodio P. Hepatic encephalopathy: historical remarks. J Clin Exp Hepatol. 2015;5:S4–6.[PubMed][CrossRef][Google Scholar]

[40]. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–25.[PubMed][CrossRef][Google Scholar]

[41]. Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC. The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 2013;141:2671–8.[PubMed][CrossRef][Google Scholar]

[42]. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: What is the evidence? Metab Brain Dis. 2013;28:221–5.[PubMed][CrossRef][Google Scholar]

[43]. Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and

meta-analysis. Hepatology. 2016;64:908–22.[PubMed][CrossRef][Google Scholar]

[44]. Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS ONE. 2016;11:e0146076.[PubMed][PubMed][CentralCrossRef][Google Scholar]

[45]. Sundaram V, Shaikh OS (July 2009). "Hepatic encephalopathy: pathophysiology and emerging therapies". Med. Clin. North Am. 93 (4): 819–36.

[46]. Bajaj JS (March 2010). "Review article: the modern management of hepatic encephalopathy". Aliment. Pharmacol. Ther. 31 (5): 537–47

[47]. Gluud, Lise Lotte; Vilstrup, Hendrik; Morgan, Marsha Y. (2016-04-18). "Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis" (PDF). The Cochrane Database of Systematic Reviews. 4

[48]. Polson J, Lee WM (May 2005). "AASLD position paper: the management of acute liver failure". Hepatology. 41 (5): 1179–97

[49]. Ferenci, P (May 2017). "Hepatic encephalopathy". Gastroenterology Report. 5 (2): 138–147.

[50]. Goh, Ee Teng; Stokes, Caroline S.; Sidhu, Sandeep S.; Vilstrup, Hendrik; Gluud, Lise Lotte; Morgan, Marsha Y. (2018-05-15). "L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis" (PDF). The Cochrane Database of Systematic Reviews.5